Virica Biotech and eXmoor Pharma have announce a new collaboration project funded by a joint UK-Canada government initiative. This project aims to enhance the manufacturing of adeno-associated vectors (AAVs) crucial for gene therapies, ultimately reducing costs and improving the accessibility of life-saving therapies. The collaborative project will utilize Virica’s VSEs™, small molecules that have been [...]
Wednesday November 20th, 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET Virica Biotech and Culture Biosciences will present innovative solutions to address the high costs associated with gene therapy manufacturing. Real-world case studies will highlight improved productivity, shorter timelines, and more efficient scale-up. Attendees will gain insights into optimizing AAV production using [...]
Virica Biotech and Ginkgo Bioworks have announced a strategic partnership aimed at improving AAV gene therapy production. Virica will provide a panel of its Viral Sensitizer Enhancers (VSETM) to Ginkgo for high-throughput AAV production screening, while Ginkgo will utilize its advanced screening platform to test VSEs directly in clients' cell lines. This collaboration is expected [...]
OTTAWA – October 4, 2021 – Virica Biotech Inc., a leading life science developer of solutions for scaling of viral medicines, announced today the first closing of its Series A financing. The round, led by Dynamk Capital, is expected to close with additional investors by the end of Q4-2021. The investment strengthens Virica’s already impressive growth trajectory, [...]
March 14, 2020—As the world deals with COVID-19, now officially deemed a pandemic, many groups are racing against the clock to develop vaccines against the novel coronavirus. The development and manufacturing of effective vaccines is a laborious and challenging task for a variety of reasons. In the pandemic situation that we and our loved ones [...]
Virica’s Founder and CEO Dr. Jean-Simon Diallo spoke in an interview with CBC on All in a Day with Alan Neal on fighting the current COVID-19 pandemic by speeding up the process of mass-producing vaccines. Virica’s VSE technology which was spun out of the Ottawa Hospital Research Institute aims to overcome the manufacturing challenges that [...]
Virica’s Founder and CEO Dr. Jean-Simon Diallo discusses his latest virology research at the Ottawa Hospital Research Institute, which focuses on Covid-19 and is funded by the Ontario Government, with CTV Ottawa Morning. His team is using a biosensor that detects the interaction with the virus and its receptor which will allow them to rapidly [...]
Virica Biotech is proud to announce a critical $1 million collaborative project with Dr. Jean-Simon Diallo's Ottawa Hospital Research Institute lab that has been selected for grant financing by BioCanRx. The primary deliverable for this project is the generation of a set of regulatory assays and procedures forming a critical path that will enable the [...]
Virica Biotech is excited to be participating in two accelerator programs: The Global US Market Expansion Accelerator – Global Soft Landing program and the Canadian Entrepreneurs in Life Sciences (CELS) program. These programs provide coaching and enable participating companies to form meaningful relationships with stakeholders, as well as establish a presence in the life sciences [...]
Hear from Ella Korets-Smith, Chief Business Officer & Co-Founder, as she presents the exciting programs that we are undertaking through our proprietary VSE technology to solve real world problems that face viral medicines.
